Showing 2,321 - 2,340 results of 10,572 for search '"tumors"', query time: 0.12s Refine Results
  1. 2321

    Leydig Cell Tumor in a Patient with 46,XX Disorder of Sex Development (DSD), Ovotesticular: A Case Report and a Review of the Literature by Steffen Gretser, Maria-Noemi Welte, Frederik Roos, Jens Köllermann

    Published 2021-01-01
    “…Upon resection, a Leydig cell tumor and an ovotestis were diagnosed. Nongerm call tumors are rare in patients with DSD. …”
    Get full text
    Article
  2. 2322

    Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging by Linhan Zhang MD, Lianmeng Zhao MS, Xue Lin MD, Sheng Zhao MD, Wenbin Pan MS, Dandan Wang MD, Zhongqi Sun MD, Jinping Li MD, Zonghui Liang MD, Rongjun Zhang MS, Huijie Jiang MD

    Published 2024-06-01
    “…Background Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases. …”
    Get full text
    Article
  3. 2323

    Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis by Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole Walsh, Catherine O’Sullivan, Tegan Smith, Geoffrey Littlejohn

    Published 2025-01-01
    “…Abstract Introduction This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA). …”
    Get full text
    Article
  4. 2324

    Tumor Necrosis Factor-α Promotes the Tumorigenesis, Lymphangiogenesis, and Lymphatic Metastasis in Cervical Cancer via Activating VEGFC-Mediated AKT and ERK Pathways by Xiao Chen, Luping Lin, Qiaoling Wu, Sang Li, Huihui Wang, Yang Sun

    Published 2023-01-01
    “…Lymphatic metastasis is a common phenomenon of cervical cancer. Tumor necrosis factor-α (TNF-α) was found to be closely associated with lymphatic cancer metastasis. …”
    Get full text
    Article
  5. 2325

    Endotoxin Triggers Tumor Initiation Events in Nontumorigenic Breast Epithelial Cells and Enhances Invasion-Related Phenotype in Pretumorigenic and Tumorigenic Breast Epithelial Cells by Farah Yassine, Sabreen F. Fostok, Nataly Naser Al Deen, Rabih S. Talhouk

    Published 2021-01-01
    “…Hence, we opted to investigate the role of inflammation in initiating and enhancing tumor-like phenotypes in nontumorigenic, pretumorigenic, and tumorigenic breast epithelial cells. …”
    Get full text
    Article
  6. 2326

    Melatonin Rescued Reactive Oxygen Species-Impaired Osteogenesis of Human Bone Marrow Mesenchymal Stem Cells in the Presence of Tumor Necrosis Factor-Alpha by Xianjian Qiu, Xudong Wang, Jincheng Qiu, Yuanxin Zhu, Tongzhou Liang, Bo Gao, Zizhao Wu, Chengjie Lian, Yan Peng, Anjing Liang, Peiqiang Su, Dongsheng Huang

    Published 2019-01-01
    “…Accumulation of reactive oxygen species (ROS), which can be induced by inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), can significantly inhibit the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). …”
    Get full text
    Article
  7. 2327
  8. 2328
  9. 2329
  10. 2330

    Potential role of circulating tumor cells and cell-free DNA as biomarkers in oral squamous cell carcinoma: A prospective single-center study. by Natsuki Eboshida, Atsuko Hamada, Mirai Higaki, Fumitaka Obayashi, Nanako Ito, Sachiko Yamasaki, Ryouji Tani, Tomoaki Shintani, Koichi Koizumi, Souichi Yanamoto

    Published 2024-01-01
    “…However, sensitive and reliable tests for monitoring their occurrence are unavailable, with the exception of PET-CT. Circulating tumor cells and cell-free DNA have emerged as promising biomarkers for determining treatment efficacy and as prognostic predictors in solid tumors such as breast cancer and colorectal cancer. …”
    Get full text
    Article
  11. 2331
  12. 2332
  13. 2333
  14. 2334
  15. 2335
  16. 2336
  17. 2337

    Rational strategies for designing next-generation oncolytic viruses based on transcriptome analysis of tumor cells infected with oncolytic herpes simplex virus-1 by Naeme Javid, Shahriyar Abdoli, Majid Shahbazi, Majid Shahbazi

    Published 2025-01-01
    “…IntroductionOncolytic herpes simplex viruses (oHSVs) are a type of biotherapeutic utilized in cancer therapy due to their ability to selectively infect and destroy tumor cells without harming healthy cells. We sought to investigate the functional genomic response and altered metabolic pathways of human cancer cells to oHSV-1 infection and to elucidate the influence of these responses on the relationship between the virus and the cancer cells.MethodsTwo datasets containing gene expression profiles of tumor cells infected with oHSV-1 (G207) and non-infected cells from the Gene Expression Omnibus (GEO) database were processed and normalized using the R software. …”
    Get full text
    Article
  18. 2338

    Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors by Maria Iacovantuono, Chiara Bonini, Ernesto Di Biase, Vinicio Magliacani, Gian Domenico Sebastiani

    Published 2025-02-01
    “… We present a case of interstitial lung disease arising in the course of antisynthetase syndrome (ASSD) in a patient with axial spondyloarthritis (ax-SpA) undergoing tumor necrosis factor-α (TNF-α) inhibitors therapy. …”
    Get full text
    Article
  19. 2339

    Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis by Zhonghua Zhao, Xiongying Jiang, Shiping Wen, Yanzhang Hao

    Published 2025-01-01
    “…PurposeThe present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.MethodsIn the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. …”
    Get full text
    Article
  20. 2340